True rifampicin resistance missed by the MGIT: prevalence of this pheno/genotype in the UK and Ireland after 18 month surveillance

Clinical Microbiology and Infection

Volumn 23, Issue 4, 2017, Pages 260-263

  Gonzalo, X ^a,b   Claxton, P ^c   Brown, T ^a   Montgomery, L ^d   Fitzgibbon, M ^d   Laurenson, I ^c   Drobniewski, F ^a,b  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^d ST JAMES S HOSPITAL   (Ireland)

Author keywords

Drug susceptibility testing; Genotypic dst; Line probe assay; Mycobacterium tuberculosis; Proportion method; Resistance ratio; Rifampicin; rpoB sequencing; Very major error

Indexed keywords

ISONIAZID; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT; TUBERCULOSTATIC AGENT;

ANALYTICAL EQUIPMENT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM EXAMINATION; BACTERIUM ISOLATE; BROTH DILUTION; CONTROLLED STUDY; GENE MUTATION; GENOTYPE; IRELAND; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIA GROWTH INDICATOR TUBE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNITED KINGDOM; DRUG EFFECTS; GENETICS; HEALTH SURVEY; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; GENOTYPE; HUMANS; IRELAND; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; POPULATION SURVEILLANCE; PREVALENCE; RIFAMPIN; TUBERCULOSIS, MULTIDRUG-RESISTANT; UNITED KINGDOM;

EID: 85008433252     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2016.11.015     Document Type: Article

References (30)

1. [1] Anuwatnonthakate, A., Whitehead, S.J., Varma, J.K., Silachamroon, U., Kasetjaroen, Y., Moolphate, S., et al. Effect of mycobacterial drug resistance patterns on patients’ survival: a cohort study in Thailand. Glob J Health Sci 5 (2013), 60–72.
2. [2] World Health Organization, WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. 2011, WHO, Geneva.
3. [3] World Health Organization, Treatment of tuberculosis. Guidelines. 4th edn., 2009, WHO, Geneva.
4. [4] Seagar, A.-L., Neish, B., Laurenson, I.F., Comparison of two in-house real-time PCR assays with MTB Q-PCR Alert and GenoType MTBDRplus for the rapid detection of mycobacteria in clinical specimens. J Med Microbiol 61 (2012), 1459–1464.
5. [5] World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis n.d. Geneva: WHO.
6. [6] Rigouts, L., Gumusboga, M., de Rijk, W.B., Nduwamahoro, E., Uwizeye, C., de Jong, B., et al. Rifampin resistance missed in automated liquid culture system for Mycobacterium tuberculosis isolates with specific rpoB mutations. J Clin Microbiol 51 (2013), 2641–2645.
7. [7] Lorian, V., Antibiotics in Laboratory Medicine. 2005, Lippincott Williams & Wilkins, Philadelphia.
8. [8] Canetti, G., Fox, W., Khomenko, A., Mahler, H.T., Menon, N.K., Mitchison, D.A., et al. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 41 (1969), 21–43.
9. [9] Palomino JC, Traore H, Fissette K, Portaels F. Evaluation of Mycobacteria Growth Indicator Tube (MGIT) for drug susceptibility testing of Mycobacterium tuberculosis n.d.
10. [10] Abuali, M.M., Katariwala, R., LaBombardi, V.J., A comparison of the Sensititre® MYCOTB panel and the agar proportion method for the susceptibility testing of Mycobacterium tuberculosis. Eur J Clin Microbiol Infect Dis 31 (2012), 835–839.
11. [11] Chun, R.F., Lauridsen, A.L., Suon, L., Zella, L a, Pike, J.W., Modlin, R.L., et al. Vitamin D-binding protein directs monocyte responses to 25-hydroxy- and 1,25-dihydroxyvitamin D. J Clin Endocrinol Metab 95 (2010), 3368–3376.
12. [12] Brown, T.J., Nikolayevskyy, V.N., Drobniewski, F.A., Typing Mycobacterium tuberculosis using variable number tandem repeat analysis. Methods Mol Biol 465 (2009), 371–394.
13. [13] Hall, L., Jude, K.P., Clark, S.L., Dionne, K., Merson, R., Boyer, A., et al. Evaluation of the Sensititre MycoTB plate for susceptibility testing of the Mycobacterium tuberculosis complex against first- and second-line agents. J Clin Microbiol 50 (2012), 3732–3734.
14. [14] Ling, D.I., Zwerling, A.A., Pai, M., Rapid diagnosis of drug-resistant TB using line probe assays: from evidence to policy. Expert Rev Respir Med 2 (2008), 583–588.
15. [15] WHO. Policy Statement: Automated Real-Time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF System. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26158191 (accessed 9 November 2015).
16. [16] Sangsayunh, P., Chuchothawon, C., Genotype MTBDR plus (Hain) test in suspected MDR-TB patients. J Med Assoc Thai 97 (2014), 1028–1032.
17. [17] Balabanova, Y., Ignatyeva, O., Fiebig, L., Riekstina, V., Danilovits, M., Jaama, K., et al. Survival of patients with multidrug-resistant TB in Eastern Europe: what makes a difference?. Thorax 71 (2016), 854–861.
18. [18] Lee, J., Armstrong, D.T., Ssengooba, W., Park, J.-A., Yu, Y., Mumbowa, F., et al. Sensititre MYCOTB MIC plate for testing Mycobacterium tuberculosis susceptibility to first- and second-line drugs. Antimicrob Agents Chemother 58 (2014), 11–18.
19. [19] Ziglam, H.M., Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 50 (2002), 1011–1015.
20. [20] Heifets, L.B., Drug Susceptibility in the Chemotherapy of Mycobacterial Infections. 1991, CRC Press, Boca Raton.
21. [21] Koneman's Color Atlas and Textbook of Diagnostic Microbiology, 2006, Lippincott Williams & Wilkins, Philadelphia.
22. [22] Krüüner, A., Yates, M.D., Drobniewski, F.A., Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis. J Clin Microbiol 44 (2006), 811–818.
23. [23] CLSI, Susceptibility testing of Mycobacteria, Nocardiae, and other aerobic Actinomycetes—Approved Standard Second Edition. CLSI Document M24–A2, 2011, CLSI, Wayne, PA.
24. [24] Yu, X., Jiang, G., Li, H., Zhao, Y., Zhang, H., Zhao, L., et al. Rifampin stability in 7H9 broth and Löwenstein–Jensen medium. J Clin Microbiol 49 (2011), 784–789.
25. [25] Ocheretina, O., Escuyer, V.E., Mabou, M.-M., Royal-Mardi, G., Collins, S., Vilbrun, S.C., et al. Correlation between genotypic and phenotypic testing for resistance to rifampin in Mycobacterium tuberculosis clinical isolates in Haiti: investigation of cases with discrepant susceptibility results. PLoS One, 9, 2014, e90569.
26. [26] Van Deun, A., Aung, K.J.M., Bola, V., Lebeke, R., Hossain, M.A., de Rijk, W.B., et al. Rifampin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol 51 (2013), 2633–2640.
27. [27] Van Deun, A., Aung, K.J.M., Hossain, A., de Rijk, P., Gumusboga, M., Rigouts, L., et al. Disputed rpoB mutations can frequently cause important rifampicin resistance among new tuberculosis patients. Int J Tuberc Lung Dis 19 (2015), 185–190.
28. [28] Hauck, Y., Fabre, M., Vergnaud, G., Soler, C., Pourcel, C., Comparison of two commercial assays for the characterization of rpoB mutations in Mycobacterium tuberculosis and description of new mutations conferring weak resistance to rifampicin. J Antimicrob Chemother 64 (2009), 259–262.
29. [29] Public Health England, Tuberculosis in the UK: Annual report on tuberculosis surveillance in the UK, 2013. 2013, PHE, London.
30. [30] Public Health England, Tuberculosis in the UK: 2014 report. 2014, PHE, London.